Abstract
In cancer, upregulation of coinhibitory B7 ligands has been associated with immune evasion. So far, anti-programmed death-1 (PD-1) and anti-PD-ligand 1 (PD-L1) antibodies have been used in immuno-oncology, with promising outcomes; however, it is still needed to identify other markers, especially for endometrial cancer (EC). EC is a gynecological malignancy historically classified into two types: type I, with mostly estrogen-dependent endometrioid diseases, and the most aggressive type II, including mainly estrogen-independent and non-endometrioid tumors. PD ligand-2 (PD-L2) is known as the second ligand of the PD-1 receptor and, upon its binding, contributes to T-cell exhaustion. Up to now, very few information are available about PD-L2 in cancers, and no data have been reported for EC. The aim of this work was to characterize the PD-L1 and PD-L2 ligand expression profile in EC cell lines, focusing the attention on the biological role of PD-L2 and its prognostic impact in human type II EC biopsies. Using in silico analysis of TCGA data, we performed a molecular profiling in a cohort of 506 patients, both types I and II, and PD-1 ligands expression was also analyzed in different primary human EC cell lines. Moreover, PD-L2 stain...Continue Reading
References
Feb 24, 2006·British Journal of Cancer·C A HamiltonJ K Chan
Nov 28, 2006·Biochimica Et Biophysica Acta·James A McCubreyRichard A Franklin
Mar 14, 2007·Molecular Human Reproduction·D GentiliniA M Di Blasio
Jan 29, 2008·Blood·Takeshi AzumaLieping Chen
Jul 16, 2010·Blood·Michael R GreenMargaret A Shipp
May 3, 2011·Trends in Biochemical Sciences·Michelle C MendozaJohn Blenis
May 23, 2012·Clinical & Developmental Immunology·Esdy N RozaliW Joost Lesterhuis
May 3, 2013·Nature·Cyriac KandothDouglas A Levine
Nov 19, 2013·Archives of Pathology & Laboratory Medicine·Patrick L FitzgibbonsSharon Nofech-Mozes
Mar 25, 2014·Cancer Immunology, Immunotherapy : CII·Anke VanderstraetenFrederic Amant
Oct 17, 2015·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Antonio CallesPasi A Jänne
Nov 6, 2015·Endocrine-related Cancer·Annu Makker, Madhu Mati Goel
Dec 8, 2015·Experimental and Therapeutic Medicine·Jia LiuYanhong Che
Dec 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J ChenX D Zhang
Feb 3, 2016·Oncology Letters·Kenzo Sonoda
Mar 26, 2016·Cancer Science·Koji TanakaHideaki Tahara
Apr 7, 2016·Oncotarget·Yusuke InoueHaruhiko Sugimura
Jul 23, 2016·Oncology Letters·Zhongfu MoZongbing You
Sep 3, 2016·Oncotarget·Zhinan MaXuesen Zhang
Sep 28, 2016·Cancer Research·Curtis A ClarkTyler J Curiel
Dec 27, 2016·Frontiers in Immunology·Kankana BardhanVassiliki A Boussiotis
Aug 12, 2017·Cancer Treatment Reviews·Jole VentrigliaChiara Della Pepa
Oct 23, 2017·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Qiu-Xia QuXue-Guang Zhang
Nov 11, 2017·Human Pathology·Poonam K PanjwaniShuchun Zhao
Dec 23, 2017·Applied Immunohistochemistry & Molecular Morphology : AIMM·Ede BirtalanLaszlo Tamas
Feb 13, 2018·Oncotarget·Niranjan AwasthiRoderich E Schwarz
Jun 21, 2018·British Journal of Cancer·Chao-Qun LiuLimin Zheng
Aug 15, 2018·International Journal of Molecular Sciences·Michiel Remmerie, Veerle Janssens
Aug 23, 2018·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Nuran SunguFazli Erdoğan
Oct 3, 2018·Signal Transduction and Targeted Therapy·David EscorsGrazyna Kochan
Oct 12, 2018·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Frédéric AmantCarien L Creutzberg
Feb 5, 2019·Oncoimmunology·Zhi-Liang WangTao Jiang
Mar 20, 2019·Cell Death & Disease·Tingting RenWei Guo
Mar 20, 2019·Journal of Gynecologic Oncology·Chiara Di TucciPierluigi Benedetti Panici
Mar 21, 2019·Frontiers in Oncology·Huayu YangYilei Mao
Apr 4, 2019·Molecular Medicine Reports·Xiang ShiXianrong Zhou
Nov 5, 2019·Frontiers in Oncology·Oliviero MarinelliMassimo Nabissi